medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Número 12

<< Anterior Siguiente >>

Ginecol Obstet Mex 2020; 88 (12)


Marcadores tumorales en cáncer de mama. Revisión sistemática

Bonilla-Sepúlveda ÓA

Idioma: Español
Referencias bibliográficas: 55
Paginas: 860-869
Archivo PDF: 191.37 Kb.


RESUMEN

Antecedentes: El cáncer de mama es el tumor maligno más frecuente en mujeres de todo el mundo. Los marcadores tumorales aprobados por la FDA son el antígeno de cáncer 15-3 (CA15-3) y el antígeno carcinoembrionario, que se utilizan con frecuencia para la detección y control del cáncer de mama.
Objetivo: Determinar la utilidad de los marcadores tumorales CA 15-3 y antígeno carcinoembrionario en la detección temprana de recurrencia, pronóstico y seguimiento de pacientes con cáncer de mama metastásico.
Metodología: Búsqueda sistemática de publicaciones en inglés en la base de datos Medline-PubMed con los términos: “biomarkers”, “tumor”, “tumor biomarkers”, “marker”, “tumor marker”, “breast neoplasms”, “breast”, “neoplasms”, “cancer”, “mucin-1”, “CA 15-3”, “carcinoembryonic antigen”. Se seleccionaron artículos originales, ensayos clínicos, revisiones, revisiones sistemáticas y metanálisis, publicados entre el 28 de marzo de 2015 y el 25 de marzo de 2020, que determinaran la utilidad del antígeno CA 15-3 y el antígeno carcinoembrionario en el cáncer de mama.
Resultados: Se seleccionaron para la redacción de este artículo 11 publicaciones trascendentales para determinar la utilidad de los marcadores tumorales en cáncer de mama.
Conclusiones: La utilidad de los marcadores tumorales antígeno 15-3 y antígeno carcinoembrionario es contradictoria y no completamente aceptada por las asociaciones de oncología y las guías internacionales; sin embargo, existe evidencia que confirma su utilidad como marcadores diagnósticos y pronósticos en el cáncer de mama.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cancer today. http://gco.iarc.fr/today/home.

  2. Redig A, McAllister S. Breast cancer as a systemic disease: a view of metastasis. J. Intern. Med. 2013; 274:113-26. doi: 10.1111/joim.12084.

  3. Sundquist M, et al. Improved survival in metastatic breast cancer 1985-2016, Breast. 2016; 31:46-50. doi: 10.1016/j. breast.2016.10.005.

  4. Taplin S, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst. 2008; 100 (12): 876-87. doi. 10.1093/jnci/djn172.

  5. Mandelblatt JS, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009; 151 (10): 738-47. doi. 10.7326/0003-4819-151-10-200911170- 00010.

  6. Duffy M. Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem. 2006; 52: 345-51. doi. 10.1373/ clinchem.2005.059832.

  7. Molina R, et al. Tumor markers in breast cancer -European Group on Tumor Markers recommendations. Tumour Biol. 2005; 26: 281-93. doi. 10.1159/000089260.

  8. Cheung K, et al. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 2000; 26: 91-102. doi. 10.1053/ctrv.1999.0151.

  9. Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007; 25: 5287-312. doi. 10.1200/JCO.2010.33.7311.

  10. Thompson JA, et al. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991; 5 (5): 344-66. doi. 10.1002/jcla.1860050510.

  11. Sulekha Dhanisha S, et al. Mucins: structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Crit Rev Oncol Hematol. 2017; 122: 98-122. doi. 10.1016/j.critrevonc.2017.12.006.

  12. Kufe D, et al. Differential reactivity of a novel monoclonal antibody (df3) with human malignant versus benign breast tumors. Hybridoma. 1984; 3 (3): 223-32. doi. 10.1089/ hyb.1984.3.223.

  13. Hayes DF, et al. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Investig. 1985; 75 (5): 1671-78. doi. 10.1172/JCI111875.

  14. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001; 6 (3): 339-53. doi. 10.1023/a:1011379725811.

  15. Roy LD, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011; 30 (12): 1449-59. doi. 10.1038/ onc.2010.526.

  16. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004; 4: 45. doi. 10.1038/nrc1251.

  17. Haddon L, Hugh J. MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/ Src signaling triad. Clin Exp Metas. 2015; 32 (4): 393-403. doi. 10.1007/s10585-015-9711-8.

  18. Wei X, et al. MUC1 oncoprotein stabilizes and activates estrogen receptor α. Mol Cell. 2006; 21 (2): 295-305. doi: 10.1016/j.molcel.2005.11.030.

  19. Merikhian P, et al. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Rev Anticancer Ther. 2017; 17 (7): 607-13. doi. 10.1080/14737140.2017.1340837.

  20. Lin DC, Genzen JR. Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. Breast Cancer Res Treat. 2018; 167 (1): 269-76. doi.10.1007/s10549-017- 4513-0

  21. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965; 21: 439-62. doi. 10.1084/jem.121.3.439.

  22. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999; 9 (2): 67-81. doi. 10.1006/scbi.1998.0119.

  23. Charbonneau J, Stanners CP. Role of carbohydrate structures in CEA-mediated intercellular adhesion. Cell Adhes Commun. 1999; 7 (3): 233-44. doi: 10.3109/15419069909010805.

  24. Kabel AM. Tumor markers of breast cancer: new prospective. J Oncol Sci. 2017; 3 (1): 5-11. doi: 10.1016/j. jons.2017.01.001.

  25. Stern N, et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol. 2005; 174 (11): 6692-701. doi: 10.4049/jimmunol.174.11.6692.

  26. Nicolini A, Carpi A. Postoperative follow‐up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol. 2000; 21 (4): 235‐48. doi: 10.1159/000030129.

  27. O’Hanlon DM, et al. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer. 1995; 71 (6): 1288-91. doi: 10.1038/bjc.1995.249.

  28. Uehara M, et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 2008; 13 (5): 447-51. doi: 10.1007/s10147-008-0773-3.

  29. Maric P, et al. Tumor markers in breast cancer -evaluation of their clinical usefulness. Coll Antropol. 2011; 35: 241-47. PMID: 21661378.

  30. Cardoso F, et al. Inconsistent criteria used in American Society of Clinical Oncology 2007. Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2008; 26: 2058-59. doi: 10.1200/JCO.2007.15.6638.

  31. NCCN guidelines Version 4. 2018 Breast cancer 2018. https ://www.nccn.org/profe ssion als/physi cian_ gls/pdf/ breas t_block s.pdf.

  32. Largillier J, et al. Prognostic factors in 1038 women with metastatic breast cancer, Ann. Oncol. 2008; 19: 2012-19. doi: 10.1093/annonc/mdn424.

  33. Mosconi P, et al. Survival, quality of life and breast cancer. Ann. Oncol. 2001; 12: S15-S19. doi: 10.1093/annonc/12. suppl_3.s15.

  34. Stieber P, et al. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer. A retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta. 2015; 448: 228-31. doi:10.1016/j.cca.2015.06.022.

  35. Shao Y, et al. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015; 10 (7): e0133830. doi:10.1371/journal.pone.0133830.

  36. Wu S, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014; 23: 88-93. doi: 10.1016/j. breast.2013.11.003.

  37. Tomlinson I, et al. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur. J. Cancer. 1995; 31A: 899-902. doi: 10.1016/0959-8049(94)00447-1.

  38. Soletormos G, et al. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur. J. Cancer. 2004; 40: 481-86. doi: 10.1016/j.ejca.2003.10.015.

  39. Colomer R, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in nonmalignant diseases. Breast Cancer Res. Treat. 1989; 13: 123-33. doi: 10.1007/BF01806524.

  40. Guadagni F, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin. Cancer Res. 2001; 7: 2357-62. PMID: 11489813.

  41. Jager W, et al. Breast cancer and clinical utility of CA 15-3 and CEA. Scand. J. Clin. Lab. Invest. Suppl. 1995; 221: 87-92. doi: 10.3109/00365519509090570.

  42. Al-Jarallah M, et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur. J. Surg. Oncol. 1993; 19: 74-79. PMID: 8436243.

  43. Engel K, et al. CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer. Geburtshilfe Frauenheilkd. 1988; 48: 309-12. doi: 10.1055/s-2008-1026508.

  44. Coveney E, et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int. J. Biol. Markers. 1995; 10: 35-41. PMID: 7629425.

  45. Ertl I, et al. CA125 in the early detection of metastatic breast cancer. http://ascopubs.org/doi/abs/10.1200/ jco.2009.27.15s.e12015.

  46. Van Poznak C, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology. Clinical Practice Guidelines. J Clin Oncol. 2015; 33 (24): 2695-704. doi: 10.1200/JCO.2015.61.1459.

  47. Li X, et al. Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: A meta-analysis including 12,993 patients. Dis Markers. 2018; 2018: 9863092. doi: 10.1155/2018/9863092.

  48. Fu Y, Li H. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis. Med Sci Monit. 2016;22:3154-62. doi: 10.12659/msm.896563.

  49. Di Gioia D, Blankenburg I, Nagel D, Heinemann V, Stieber P. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clin Chim Acta. 2016;461:1-7. doi: 10.1016/j. cca.2016.07.014.

  50. Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao X, Jing J. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017;470:51-55. doi: 10.1016/j. cca.2017.04.023.

  51. Fujimoto Y, Higuchi T, Nishimukai A, Miyagawa Y, Kira A, Ozawa H, Bun A, Imamura M, Miyoshi Y. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. J Surg Oncol. 2018;118(1):228-237. doi: 10.1002/jso.25125.

  52. Nicolini A, Carpi A, Ferrari P, Morganti R, Mazzotti V, Barak V, Duffy MJ. An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag Res. 2018;10:6879-6886. doi: 10.2147/CMAR.S177522.

  53. Bayo J, Castaño MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. Clin Transl Oncol. 2018;20(4):467-475. doi: 10.1007/s12094-017-1731-1.

  54. Imamura M, et al. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol. 2018; 16 (1): 26. doi. 10.1186/s12957-018- 1325-6.

  55. Nam SE, et al. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Breast Cancer Res Treat. 2019; 177 (3): 669-78. doi. 10.1007/s10549-019-05357-y.




2020     |     www.medigraphic.com